Clinical Trials Browser

ALK Positive Non-small Cell Lung Cancer

NCT07556549 2026-05-22

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Active not recruiting

50 enrolled

Thoracic

Non-Small Cell Lung Cancer ALK-positive

NCT05297890 2026-05-19

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

70 enrolled

Thoracic

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Active not recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07415005 2026-05-05

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

30 enrolled

Thoracic

Advanced Non-Small Cell Lung Cancer

NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Thoracic

Lung Neoplasms

NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Active not recruiting

41 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

56 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Phase EARLY_PHASE1 Recruiting

15 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Completed

73 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2 Active not recruiting

54 enrolled

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1 Completed

65 enrolled 38 charts

CNS

Neuroblastoma

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Tumor-Agnostic

Carcinoma

Clinical Trials

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Lorlatinib Continuation Study

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer